ym 529 has been researched along with Age-Related Osteoporosis in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (17.65) | 29.6817 |
| 2010's | 23 (67.65) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA | 1 |
| Hagino, H; Hirakawa, A; Ito, M; Matsumoto, T; Nakano, T; Soen, S; Takeuchi, T; Tanaka, S; Tanaka, Y; Yamamoto, K | 1 |
| Endo, I; Matsumoto, T | 2 |
| Habe, K; Hagimori, K; Iida, S; Isono, K; Matsushima, Y; Mizutani, K; Okada, K; Umaoka, A; Yamanaka, K; Yamazaki, H | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
| Hagino, H; Mori, S; Nakamura, T; Ohta, H; Sone, T; Uemura, Y | 1 |
| Banno, T; Fujita, T; Matsuyama, Y; Nishida, T; Ohishi, T; Okabayashi, R; Suzuki, D; Ushirozako, H; Yamamoto, K | 1 |
| Emoto, M; Hayashi, N; Imanishi, Y; Inaba, M; Miyaoka, D; Mori, K; Nagata, Y; Ohara, M; Yamada, S | 1 |
| Choe, H; Harigane, K; Inaba, Y; Kumagai, K; Kusayama, Y; Saito, T; Tezuka, T | 1 |
| Asukai, M; Fujita, T; Matsuyama, Y; Nishida, T; Ohishi, T; Suzuki, D | 1 |
| Abe, A; Hasegawa, E; Ishikawa, H; Ito, S; Kobayashi, D; Murasawa, A; Nakazono, K; Narita, I; Nomura, Y; Otani, H; Takai, C | 1 |
| Morio, Y; Tanishima, S | 1 |
| Fukunaga, M; Hagino, H; Matsumoto, T; Nakamura, T; Nakano, T; Ohashi, Y; Shiraki, M; Takaoka, K | 1 |
| Akimoto, T; Ando, Y; Iwazu, K; Kitamura, M; Kobayashi, T; Komada, T; Kusano, E; Morishita, Y; Muto, S; Numata, A; Saito, O; Takemoto, F; Yamamoto, H; Yumura, W | 1 |
| Bando, K; Endo, Y; Hasegawa, M; Kim, S; Kiyama, T; Okada, S; Sasaki, K; Sugawara, S; Takano-Yamamoto, T; Tanaka, Y; Yamaguchi, K | 1 |
| Amano, N; Honda, Y; Iwamoto, J; Sato, Y | 1 |
| Arita, S; Fukuda, F; Ikeda, S; Matsumoto, H; Nagashima, M; Okazaki, Y; Okimoto, N; Sakai, A; Teshima, K; Tsurukami, H; Yoshioka, T | 1 |
| Kawabata, K; Kawada, N; Kayasuga, R; Mori, H; Ochi, Y; Tanaka, M; Yamada, H | 1 |
| Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T | 1 |
| Ebina, K; Hirao, M; Kaneshiro, S; Noguchi, T; Tsukamoto, Y; Yoshikawa, H | 1 |
| Iida, S; Ikeda, A; Matsubara, M; Matsumura, T; Moritani, N; Yamachika, E | 1 |
| Ikumi, N; Inomata, H; Iwata, M; Karasawa, H; Kitamura, N; Matsukawa, Y; Nagasawa, Y; Nozaki, T; Shiraiwa, H; Sugiyama, K; Takei, M | 1 |
| Ito, M; Kono, S; Tanaka, S; Yoshida, A | 1 |
| Abe, K; Aihara, T; Akazawa, T; Aoki, Y; Eguchi, Y; Fujimoto, K; Furuya, T; Hanaoka, E; Hirayama, J; Inage, K; Inoue, M; Ishikawa, T; Kanamoto, H; Kinoshita, H; Kinoshita, T; Koda, M; Kotani, T; Kubota, G; Murata, Y; Nemoto, T; Ohtori, S; Orita, S; Sainoh, T; Sakuma, T; Sato, J; Shiga, Y; Suseki, K; Suzuki, M; Takahashi, K; Yamagata, M; Yamashita, M; Yamauchi, K | 1 |
| Nakatoh, S | 1 |
| Kawada, N; Kayasuga, R; Kishikawa, K; Mori, H; Ochi, Y; Tanaka, M; Yamada, H | 1 |
| Fukunaga, M | 1 |
| Matsumoto, T | 1 |
| Masuda, H; Tanaka, S | 1 |
| Aoyama, K; Kimoto, A; Minamide, T; Miyata, K; Mori, H; Mori, M; Nozaki, K; Sasamata, M; Shimizu, K; Shimokawa, K; Suzuki, H; Tanaka, M; Usui, T; Yamamotoya, H | 1 |
| Fujimori, J; Kubo, T; Matsuo, T; Ochi, M; Shimose, S | 1 |
| Fukunaga, M; Hagino, H; Ito, M; Matsumoto, T; Mizunuma, H; Nakamura, T; Nishizawa, Y; Ohashi, Y; Okazaki, R; Shiraki, M; Sone, T | 1 |
| Miki, T; Minamide, T | 1 |
7 review(s) available for ym 529 and Age-Related Osteoporosis
| Article | Year |
|---|---|
Minodronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Japan; Osteoporosis | 2020 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
A review of minodronic acid hydrate for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures | 2013 |
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Topics: Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Peptides | 2009 |
[Drugs under development for osteoporosis ].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cathepsin K; Cathepsins; Denosumab; Diphosphonates; Drug Design; Humans; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes | 2009 |
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures | 2009 |
[Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteoporosis; Rats; Spinal Fractures | 2007 |
13 trial(s) available for ym 529 and Age-Related Osteoporosis
| Article | Year |
|---|---|
Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Imidazoles; Male; Middle Aged; Osteoporosis; Spinal Fractures; Young Adult | 2020 |
Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.
Topics: Accidental Falls; Aged; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Multivariate Analysis; Osteoporosis; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures | 2021 |
Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Cancellous Bone; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Osteoporosis; Osteoporotic Fractures; Teriparatide | 2017 |
Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Risedronic Acid | 2018 |
Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Spinal Fractures | 2013 |
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risedronic Acid | 2013 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Patient Preference; Risedronic Acid | 2016 |
Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Topics: Aged; Aged, 80 and over; Animals; Biomarkers; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Time Factors; Vitamin D; Vitamin K 2 | 2016 |
Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Glucocorticoids; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prospective Studies; Time Factors; Tokyo; Treatment Outcome | 2018 |
Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Osteoporosis; Retrospective Studies; Spinal Fractures; Time Factors; Time-to-Treatment; Treatment Outcome | 2017 |
The nature of osteoporotic low back pain without acute vertebral fracture: A prospective multicenter study on the analgesic effect of monthly minodronic acid hydrate.
Topics: Aged; Aged, 80 and over; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Low Back Pain; Male; Osteoporosis; Pain Measurement; Prospective Studies; Spinal Fractures; Treatment Outcome | 2017 |
Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Tartrate-Resistant Acid Phosphatase; Teriparatide; Vitamin D | 2018 |
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Treatment Outcome | 2012 |
14 other study(ies) available for ym 529 and Age-Related Osteoporosis
| Article | Year |
|---|---|
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Etidronic Acid; Humans; Lactates; Organophosphonates; Organophosphorus Compounds; Osteoporosis; Protein Prenylation; rab GTP-Binding Proteins; Risedronic Acid; Stereoisomerism | 2010 |
Inflammatory Skin-Derived Cytokines Accelerate Osteoporosis in Mice with Persistent Skin Inflammation.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Caspase 1; Cytokines; Diphosphonates; Female; Femur; Imidazoles; Mice; Mice, Inbred C57BL; Osteoporosis; Psoriasis; Regional Blood Flow | 2020 |
Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients.
Topics: Aged; Aged, 80 and over; Arginine; Bone Density; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Lysine; Middle Aged; Osteoporosis; Outcome Assessment, Health Care | 2017 |
Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Homocysteine; Humans; Imidazoles; Kidney; Linear Models; Osteoporosis; Peptide Fragments; Peptides; Procollagen | 2019 |
The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Glucocorticoids; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome | 2018 |
Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate).
Topics: Acute Kidney Injury; Administration, Oral; Aged; Bone Density Conservation Agents; Creatinine; Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Male; Nephrotic Syndrome; Osteoporosis | 2013 |
Inflammatory and necrotic effects of minodronate, a nitrogen-containing bisphosphonate, in mice.
Topics: Analysis of Variance; Animals; Diphosphonates; Female; Humans; Imidazoles; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Molecular Structure; Osteonecrosis; Osteoporosis; Periodontal Ligament; Radiography; Tibia | 2013 |
Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Gastrointestinal Diseases; Humans; Imidazoles; Low Back Pain; Male; Medication Adherence; Middle Aged; Osteoporosis; Patient Preference; Prospective Studies; Treatment Outcome | 2014 |
Effect of intermittent and daily regimens of minodronic Acid on bone metabolism in an ovariectomized rat model of osteoporosis.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; X-Ray Microtomography | 2014 |
Treatment of Osteonecrosis of the Jaw.
Topics: Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Regeneration; Dental Fistula; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Fractures; Osteoporosis; Teriparatide; Wound Healing | 2015 |
Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Topics: Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Inbred F344; Stress, Mechanical | 2008 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Minodronate for the treatment of osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Dogs; Drug Evaluation, Preclinical; Female; Fractures, Bone; Haplorhini; Humans; Imidazoles; Osteoporosis; Rats | 2010 |
[New approved drugs for osteoporosis in Japan].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Indoles; Japan; Osteoporosis; Parathyroid Hormone; Teriparatide; Vitamin D | 2012 |